DiaMedica Therapeutics (NASDAQ:DMAC) (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.
DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival. DiaMedica has advanced DM199 through early‐stage clinical trials to assess safety, tolerability and preliminary efficacy. In parallel, the company is exploring additional indications for DM199, including diabetic kidney disease, leveraging its mechanism of action to address vascular and inflammatory pathways implicated in renal dysfunction.
Headquartered in Minneapolis, Minnesota, DiaMedica operates primarily in the United States while engaging with regulatory authorities and research collaborators to support its clinical programs. As a NASDAQ‐listed entity, the company maintains a corporate strategy centered on building a proprietary pipeline, advancing clinical milestones and pursuing partnerships that can accelerate development and broaden global reach.
DiaMedica is led by President and Chief Executive Officer Atul Koria, whose background spans drug development and strategic alliances in the biotechnology sector. Under his guidance, the company continues to focus on advancing DM199 through the clinic, with the goal of delivering innovative therapeutic options for patients suffering from stroke, kidney disease and other central nervous system disorders.
